N-(5-hydroxy-pyridin-2-yl)benzamide | 69634-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-hydroxy-pyridin-2-yl)benzamide
• 英文别名: 2-Benzoylamino-5-hydroxy-pyridin；6-benzoylamino-pyridin-3-ol；N-(5-hydroxy-[2]pyridyl)-benzamide；N-(5-Hydroxy-[2]pyridyl)-benzamid；N-(5-Hydroxy-pyridin-2-yl)-benzamide；N-(5-hydroxypyridin-2-yl)benzamide
• CAS: 69634-17-9
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: HRDNNQNXXUJEJF-UHFFFAOYSA-N

物化性质

• 熔点：
  181-182 °C(Solv: methanol (67-56-1))
• 沸点：
  381.8±27.0 °C(Predicted)
• 密度：
  1.339±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(5-hydroxy-pyridin-2-yl)benzamide 在 氢溴酸 作用下， 生成 6-aminopyridin-3-ol
  参考文献：
  名称：

  Heterocyclic Studies. VII. The Preparation and Reactions of 2-Amino-5-hydroxypyridines; the Formation of an Azaquinone¹

  摘要：

  DOI：

  10.1021/ja01531a047
• 作为产物：
  描述：

  5-羟基-2-(4-硝基苯基偶氮)吡啶 在 palladium on activated charcoal 、 溶剂黄146 作用下， 生成 N-(5-hydroxy-pyridin-2-yl)benzamide
  参考文献：
  名称：

  Heterocyclic Studies. VII. The Preparation and Reactions of 2-Amino-5-hydroxypyridines; the Formation of an Azaquinone¹

  摘要：

  DOI：

  10.1021/ja01531a047

文献信息

• [EN] INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE DIHYDROCÉRAMIDE DÉSATURASE POUR LE TRAITEMENT DE MALADIES
  申请人：CENTAURUS THERAPEUTICS

  公开号：WO2018112077A1

  公开（公告）日：2018-06-21

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

  本文披露了二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物在治疗疾病方面非常有用，如代谢性疾病、心血管疾病、纤维化疾病、自身免疫/慢性炎症性疾病、囊性纤维化、各种癌症、神经退行性疾病、脂质储存障碍和缺血/再灌注损伤，预期通过抑制Des1对患者具有治疗作用。还提供了在人类或动物受试者中抑制Des1活性的方法。
• Compounds Effecting Glucokinase
  申请人：Boyd Scott

  公开号：US20080207636A1

  公开（公告）日：2008-08-28

  The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

  本发明涉及使用化合物式(I)或其盐、溶剂化物或前药，其中R1、R2、R3、n和m如规范所述，在制备治疗或预防通过葡萄糖激酶（GLK）介导的疾病状态，如2型糖尿病的药物。本发明还涉及一类新的化合物式(I)和制备化合物式(I)的方法。
• Inhibitors of dihydroceramide desaturase for treating disease
  申请人：Centaurus Therapeutics

  公开号：US11135207B2

  公开（公告）日：2021-10-05

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

  本公开涉及二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物和组合物在治疗某些疾病（例如代谢性疾病、心血管疾病、纤维化疾病、自身免疫性疾病/慢性炎症性疾病、囊性纤维化、多种癌症、神经退行性疾病、脂质沉积障碍及缺血/再灌注损伤）时是有用的，且预期对于患者而言Des1的抑制具有治疗作用。本发明还提供了抑制人类或动物受试者Des1活性的方法。
• INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
  申请人：Centaurus Therapeutics

  公开号：US20190328720A1

  公开（公告）日：2019-10-31

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
• US7524957B2
  申请人：——

  公开号：US7524957B2

  公开（公告）日：2009-04-28